TABLE 3.

Association of virological and clinical outcomes with resistance mutationsa

PredictorSlope (Pb) for:
Virological outcomecClinical outcomed
Univariate analyses
    Baseline clinical and biological     characteristics
        CDC clinical stage (1-3)0.085 (0.663)0.606 (<0.001)
        CD4 cell counts (log10 cells/μl)−0.800 (0.009)−0.156 (0.081)
        Number of prior NRTIs0.080 (0.853)0.500 (0.001)
        Sum of key RT mutations at     baseline2.306 (0.001)2.000 (<0.001)
    Sum of key PRO mutationse (3-monthly)0.348 (0.013)0.235 (<0.001)
Multivariate analyses
    Sum of key PRO mutations0.337 (0.020)0.159 (<0.001)
    Sum of key RT mutationse at baseline0.214 (0.690)0.807 (0.003)
    Baseline CD4 cells count (log10 cells/μl)−0.823 (0.061)
    Baseline CDC clinical stage (1-3)0.556 (<0.001)
  • a The association between predictors and end points was measured by the slope coefficient of a weighted linear mixed-effect regression. Predictors were baseline patient characteristics or the sum of drug resistance mutations (95 samples from 26 patients, one per supplementary mutation; mixtures were scored as 0.5). End points were virological and clinical outcomes. Separate univariate models identified significant predictors (i.e., confounders). P values were further adjusted in multivariate analyses for the confounders.

  • b Values less than 0.05 are in bold.

  • c Log10-transformed changed compared to baseline values, from 6 months on.

  • d Number of new CDC stage B and C events (a change of stage was double-scored), from 3 months on.

  • e Key PRO mutations: M46I, G48V, I54V, V82A or -F, and L90M (time-dependent predictors).